Veröffentlichungen 2010

1. Altmann A, Eisenhut M, Bauder-Wüst U, Markert A, Askoxylakis V, Hess-Stumpp H, Haberkorn U. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 2010;37(12):2286-2297.

2. Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010;10:105.

3. Askoxylakis V, Garcia-Boy R, Rana S, Krämer S, Hebling U, Mier W, Altmann A, Markert A, Debus J, Haberkorn U. A New Peptide Ligand for Targeting Human Carbonic Anhydrase IX, Identified through the Phage Display Technology. PLoS One 2010;5(12):e15962.

4. Behren A, Kamenisch Y, Muehlen S, Flechtenmacher C, Haberkorn U, Hilber H, Myers JN, Bergmann Z, Plinkert PK, Simon C. Development of an oral cancer recurrence mouse model after surgical resection. Int J Oncol 2010;36(4):849-55.

5. Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, Unterberg A, Karapanagiotou-Schenkel I, Combs SE, Nikoghosyan A, Bischof M, Jäkel O, Huber P, Kulozik AE, Debus J. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer 2010;12;10:96.

6. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, Lehner B, Haberkorn U, Stroebel P, Kasper B. Impact of Dynamic 18F-FDG PET on the Early Prediction of Therapy Outcome in Patients with High-Risk Soft-Tissue Sarcomas After Neoadjuvant Chemotherapy: A Feasibility Study. J Nucl Med 2010;51:551-558.

7. Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Parametric imaging: a promising approach for the evaluation of dynamic PET-18F-FDG studies – the DKFZ experience. Hell J Nucl Med 2010;13(1):18-22.

8. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, Kasper B. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG-PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010;37:1481-1489.

9. Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, Schmieder K, Eisenhut M, Haberkorn U, Strauss LG. Pharmacokinetic studies of 68Ga-labeled Bombesin (68Ga-BZH3) and 18F-FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med 2011;36(2):101-8.

10. Duerr J, Gruner M, Schubert SC, Haberkorn U, Bujard H, Mall MA. Use of a New Generation Reverse Tetracycline Transactivator System for Quantitative Control of Conditional Gene Expression in the Murine Lung. Am J Respir Cell Mol Biol 2010; [Epub ahead of print].

11. Eder M, Krivoshein AV, Backer M, Backer JM, Haberkorn U, Eisenhut M. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol 2010;37(4):405-12.

12. Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, Haberkorn U, Mier W, Eisenhut M. (68)Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 2010;37(7):1397-1407.

13. Essig M, Rohrer M, Giesel F, Tüttenberg J, Weber MA, Michaely H, Gerigk L, Voth M. Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol 2010;20:218-226.

14. García Boy R, Mier W, Nothelfer EM, Altmann A, Eisenhut M, Kolmar H, Tomaszowski M, Krämer S, Haberkorn U. Sunflower Trypsin Inhibitor 1 Derivatives as Molecular Scaffolds for the Development of Novel Peptidic Radiopharmaceuticals. Mol Imaging Biol 2010;12(4):377-385.

15. Gerigk L, Stieltjes B, Weber MA, Giesel FL, Dimitrakopoulou-Strauss A, Essig M. Therapiemonitoring mit bildgebenden Verfahren im modernen Management von Hirntumoren. J Neurol Neurochir Psychiatr 2010;11 (1), 36-44.

16. Giesel FL, Essig M, Zabel-Du-Bois A, Bock M, Tengg-Kobligk H v, Afshar-Omarei A, Debus J, Kauczor HU, Krix M. High-contrast computed tomographic angiography better detects residual intracranial arteriovenous malformations in long-term follow-up after radiotherapy than 1.5-Tesla time-of-flight magnetic resonance angiography. Acta Radiologica 2010;51(1):64-70.

17. Giesel FL, Mehndiratta A, Essig M. High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol 2010;20(10):2461-2474.

18. Giesel FL, Runge V, Kirchin M, Mehndiratta A, Gerigk L, Corell B, von Gall C, Kauczor HU, Essig M. Three-Dimensional Multiphase Time-Resolved Low-Dose Contrast-Enhanced Magnetic Resonance Angiography Using TWIST on a 32-Channel Coil at 3 T: A Quantitative and Qualitative Comparison of a Conventional Gadolinium Chelate With a High-Relaxivity Agent. J Comput Assist Tomogr 2010;34(5):678-83.

19. Gimpel C, Masioniene L, Djakovic N, Schenk JP, Haberkorn U, Tönshoff B, Schaefer F. Complications and long-term outcome of primary obstructive megaureter in childhood. Pediatr Nephrol 2010;25(9):1679-
1686.

20. Haberkorn U, Askoxylakis V, Markert A, Altmann A. [Iodidenrichement in malignant tumours after gene transfer.] Nuklearmedizin 2010;49(61):21-25.

21. Hauser T, Gerigk L, Giesel F, Schuster L, Essig M. MR spectroscopy in dementia. Radiologe 2010;50(9):791-798.

22. Hauser T, Thomann P, Giesel FL, Schröder J, Essig M. Normal aging of the Brain. Journal of Magnetic Resonance Imaging JMRI 2010; in print.

23. Jensen AD, Muenter MW, Bischoff HG, Haselmann R, Haberkorn, U, Huber, PE. Combined treatment NSCLC stage III with intensity-modulated RT and cetuximab: the NEAR trial. Cancer 2010; in print.

24. Kasper B, Hohenberger P, Strauss LG, Dimitrakopoulou-Strauss A. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas. Hell J Nucl Med 2010;13(1):40-44.

25. Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, Hohenberger P. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging 2010;37:1876-1882.

26. Kommera H, Kaluðeroviæ GN, Bette M, Kalbitz J, Fuchs P, Fulda S, Mier W, Paschke R. In vitro anticancer studies of alpha- and beta-d-glucopyranose betulin anomers. Chem Biol Interact 2010;29;185(2:128-36.

27. Kotzerke J, Oehme L, Lindner O, Hellwig D. Arbeitsausschuss PET der DGN. [Positron emission tomographie 2008 in Germany – Results of the query and current status]. Nuklearmedizin 2010;49(2):58-64.

28. Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Lerch H, Gerss J, Frankewitsch T, Schober O, Riemann B; MSDS study group. Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial. Eur J Endocrinol 2010;163(4):637-644.

29. Kratochwil C, Giesel FL, López-Benítez R, Schimpfky N, Kunze K, Eisenhut M, Kauczor HU, Haberkorn U. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC-PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010;16(10):2899-2905.

30. Kratochwil C, Haberkorn U, Giesel FL. [PET/CT for diagnostics and therapy 9stratifi-cation of lung cancer.] Radiologe 2010;50(8):684-691.

31. Kubas H, Schäfer M, Bauder-Wüst U, Eder M, Oltmanns D, Haberkorn U, Mier W, Eisenhut M. Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding. Nucl Med Biol 2010;37(8):885-91.

32. Millonig G, Giesel FL, Reimann FM, Topalidis T, Seitz HK, Mueller S. Gastrointestinal Stromal Tumor in a Patient with Undiagnosed Neurofibromatosis Type I: an Uncommon Cause of Extrahepatic Cholestasis. Z Gastroenterol 2010;48(4):479-481.

33. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D, Kalinski P. PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 2010;116(9):1454-1459.

34. Nimmagadda S, Mangner TJ, Lawhorn-Crews JM, Haberkorn U, Shields AF. Herpes simplex virus thymidine kinase imaging in mice with (1-(2'-deoxy-2'-[(18)F]fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2'-deoxy-2'-[(18)F] fluoro-1-beta-D-arabinofuranosyl)-5-uracil). Eur J Nucl Med Mol Imaging 2009; Jun 9. [Epub ahead of print].

35. Nissen F, Kraft TE, Ruppert T, Eisenhut M, Haberkorn U, Mier W: Hot or not-the influence of elevated temperature and microwave irradiation on the solid phase synthesis of an affibody. Tetrahedron Letters 2010;51(48):6216-6219.

36. Rengier F, Mehndiratta A, von Tengg-Kobligk H, Zechmann CM, Unterhinninghofen R, Kauczor HU, Giesel FL. 3D printing based on imaging data: review of medical applications. Int J Comput Assist Radiol Surg 2010;5(4):335-341.

37. Riemann B, Krämer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Sauerland C, Frankewitsch T, Schober O; MSDS study group. Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin 2010;49(3):79-84.

38. Sarko D, Beijer B, Boy RG, Nothelfer EM, Leotta K, Eisenhut M, Altmann A, Haberkorn U, Mier W. The Pharmacokinetics of Cell-Penetrating Peptides. Mol Pharm 2010;76:2224-31.

39. Sartorius A, Kiening KL, Kirsch P, Gall CC v, Haberkorn U, Unterberg AW, Henn FA, Meyer-Lindenberg A. Remission of Major Depression under Deep Brain Stimulation of the Lateral Habenula in a Therapy-refractory Patient. Biological Psychiatry 2010;67:9-11.

40. Scheenen TWJ, Fütterer J, Weiland E, van Hecke P, Lemort M, Zechmann CM, Schlemmer HP, Broome D, Villeirs G, Lu J, Barentsz J, Roell S, Heerschap A. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol 2010; in print.

41. Schieck A, Müller T, Schulze A, Haberkorn U, Urban S, Mier W. Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. Molecules 2010;15(7):4773-4783.

42. Schuler A, Reuss J, Delorme S, Hagendorff A, Giesel F. Costs of Clinical Ultrasound Examinations - An Economical Cost Calculation and Analysis. Ultraschall in Med 2010;31(4):379-386.

43. Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 2010;84(4):1989-2000.

44. Strauss LG, Koczan D, Klippel S, Pan L, Cheng C, Haberkorn U, Willis S, Dimitrakopoulou-Strauss A. Impact of Cell-Proliferation-Associated Gene Expression on 2-Deoxy-2-[(18)F]fluoro-D: -Glucose (FDG) Kinetics as Measured by Dynamic Positron Emission Tomography (dPET) in Colorectal Tumors. Mol Imaging Biol 2010; in print. [Epub ahead of print].

45. Strauss LG, Pan L, Cheng C, Haberkorn U, Dimitrakopoulou-Strauss A. Shortened acquisition protocols for the quantitative assessment of the 2-tissue compartment model using dynamic PET-CT (dPET-CT) F-18-Deoxyglucose (FDG) studies. J Nucl Med 2010; in print.

46. Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A. Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. Br J Cancer 2010;103(2):196-200.

47. Weber MA, Henze M, Tüttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU, Essig M. Biopsy Targeting Gliomas: Do Functional Imaging Techniques Identify Similar Target Areas? Invest Radiol 2010;45(12):755-768.

48. Zechmann CM, Simpfendörfer T, Giesel FL, Zamecnik P, Thieke C, Hielscher T, Meinzer HP, Delorme S. Comparison of peripheral zone and central gland volume in patients undergoing intensity-modulated radiotherapy. J Comput Assist Tomogr 2010;34(5):739-45.

49. Zechmann CM, Buchheidt D, Hildenbrand R, Teubner J. B-Cell-Lymphoma of the female breast: Comparison of Mammography, Ultrasound and Dynamic MRI. Ultraschall Med 2010; 31(1):71-3.

1. Giesel FL, Anandaraj P, Zechmann C, Mehndiratta A. Nuclear Medicine. In: Miller CG, Krasnow J, Schwartz LH (eds.) An overview of Imaging Techniques, Clinical Applications and Trials in Clinical Trials. Springer Verlag 2010; in print.

2. Giesel FL, Tengg-Kobligk H. Contrast Media in MRI in Imaging in Clinical Trials in Medical Imaging in Clinical Trials. In: Miller CG, Krasnow J, Schwartz LH (eds.) Springer Verlag 2010; in print.

3. Giesel FL, Kratochwil C. New approaches on radio-peptide therapy delivery in patients with somatostatin receptor positive tumors in Drug Delivery Applications of Noninvasive Imaging: Validation from Biodistribution to Sites of Action. In: Jackson EF, Tian M, Li C. Wiley-Blackwell John Wiley & Sons, Inc 2010; in print.

4. Haberkorn U. Nuklearmedizinische Diagnostik von Infektionen. In: Dommisch K, Lorenz D, Ekkernkamp A (ed.) Chirurgie und Infektionen. Kaden Verlag Heidelberg: in press. ISBN 9783922777397.

5. Haberkorn U. Endoradiotherapie mit spezifischen und unspezifischen Verfahren. In: Siewert JR, Rothmund M, Schumpelik V. (eds.) Praxis der Viszeralchirurgie: Onkologische Chirurgie. Springer-Verlag 2010; pp 333-340. ISBN 9783642038075.

6. Strauss LG, Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) Applications. In: Lindon J, Tranter G, Koppenaal D (eds.) Encyclopedia of Spectroscopy and Spectrometry. 2nd edition, Vol 3. Oxford: Elsevier; 2010; pp. 2247–2252. ISBN 9780123744173.

7. Zechmann C. Kapitel Radiologie. In: Mediscript. Hammerexamen 10/2006 –4/2010 Alle Original-IMPP-Prüfungsfragen des 2. Abschnitts der Ärztlichen Prüfung, CD-Rom. Urban & Fischer bei Elsevier; 2010; ISBN 978343743891-2.